Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases

Brain metastases constitute a challenge in the management of patients with HER2-positive breast cancer treated with anti-HER2 systemic therapies. Here we sought to define the repertoire of mutations private to or enriched for in HER2-positive brain metastases. Massively parallel sequencing targeting...

Descripción completa

Detalles Bibliográficos
Autores principales: De Mattos-Arruda, Leticia, Ng, Charlotte K. Y., Piscuoglio, Salvatore, Gonzalez-Cao, Maria, Lim, Raymond S., De Filippo, Maria R., Fusco, Nicola, Schultheis, Anne M., Ortiz, Carolina, Viteri, Santiago, Arias, Alexandra, Macedo, Gabriel S., Oliveira, Mafalda, Gomez, Patricia, Teixidó, Cristina, Nuciforo, Paolo, Peg, Vicente, Saura, Cristina, Ramon y Cajal, Santiago, Casas, Francesc Tresserra, Weigelt, Britta, Cortes, Javier, Seoane, Joan, Reis-Filho, Jorge S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945519/
https://www.ncbi.nlm.nih.gov/pubmed/29755676
http://dx.doi.org/10.18632/oncotarget.25041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945519/
https://www.ncbi.nlm.nih.gov/pubmed/29755676
http://dx.doi.org/10.18632/oncotarget.25041

Ejemplares similares